Phase 1 Study of PD 0332991 Plus Bortezomib in Patients with Previously Treated Mantle Cell Lymphoma

Study Status

Open to Enrollment

Study Description

Mantle cell lymphoma is characterized by a genetic defect that results in increased production of a protein called Cyclin D1. Another protein called Cdk4/6 works together with Cyclin D1 to release a brake on cell replication. For that reason, mantle cell lymphoma cells replicate more rapidly than other cells.

PD 0332991 is an investigational oral drug (i.e., a pill) that specifically inhibits Cdk4/6. Data from our lab and from an earlier clinical trial performed at Weill Cornell Medical Center suggest that PD 0332991 is able to stop lymphoma cells from replicating in some patients with mantle cell lymphoma.

Bortezomib (Velcade) is approved by the FDA for treatment of patients with relapsed mantle cell lymphoma. Data from our laboratory suggests that PD 0332991 and bortezomib can work together to kill lymphoma cells more effectively than either drug alone.

In this study, we are testing different doses of the combination of PD 0332991 and bortezomib. We hope to learn how to safely combine the two drugs. We also hope to learn more about how both drugs work so that we can use them more effectively in the future.

Click here to visit our lymphoma blog.

Disease Status and/or Stage

Mantle Cell Lymphoma (MCL)


Weill Cornell Medical College

Key Eligibility

  • Mantle Cell Lymphoma
  • At least one prior therapy
  • Detailed eligibility discussed when you contact the study team

Principal Investigator

John Leonard, MD


Healthy Volunteers


As a healthy volunteer in a clinical trial you may make a significant contribution to the discovery of medical knowledge and new treatments that could impact people around the world.
Click here for studies seeking healthy volunteers.

Contact Us

For general inquiries, or if you need assistance finding a study, please contact:

Robert Hagerty
Subject Recruitment Manager
Tel: (646) 962-9340
[email protected]

Top of page